As a long-term advocate for improved Alzheimer’s disease therapies, we are urging the European Medicines Agency (EMA) and the Committee for Medicinal Products for Human Use (CHMP) to support conditional approval of oral Blarcamesine (ANAVEX2-73) for early Alzheimer’s disease.

Current treatment options for Alzheimer’s patients are extremely limited, and many are unsuitable due to adverse effects, complexity, or accessibility barriers. Blarcamesine’s latest clinical data demonstrates significant cognitive and functional benefits—especially in precisely identified subgroups (e.g., SIGMAR1 and COL24A1 wild-type patients)—and shows a favorable safety and tolerability profile compared to existing infusion therapies.

Many patients are unable to access antibody-based infusions or suffer intolerable side effects. An oral and well-tolerated therapeutic option addresses a critical unmet need, improves quality of life, and expands real-world accessibility for thousands.

The clinical evidence highlights responder populations where the benefits are substantial and clinically meaningful. EMA approval is essential to give hope and options to Alzheimer’s families who have waited too long for meaningful innovation.

Please join us in urging the EMA and CHMP to recognize the medical necessity and strong evidence for at least a conditional approval of oral Blarcamesine for those patients most likely to benefit.

The total number of signatures collected up to Nov 30 will be forwarded to the EMA’s portal.